A repurposing review discussed anticancer effects of midazolam in experimental systems. Those findings did not establish benefit from routine procedural sedation.
The authors described midazolam-associated apoptosis and reduced proliferation in several tumor-cell systems, with some animal evidence. Proposed pathways included caspase activation and changes in growth and survival signaling.
These observations concerned defined experimental exposures and cancer models. They did not show that every cell type responds identically or that a sedative dose produces the same exposure in a tumor.
Cell death in culture is not evidence of improved patient survival, and a molecular pathway does not establish a clinically useful therapeutic window. A narrative review also inherits differences in the methods and quality of its underlying studies.
The paper cannot justify calling midazolam an established anticancer therapy. Forensic interpretation should separate experimental activity, proposed repurposing, and the actual indication for an administration. Sedation during cancer care does not itself establish an intent or effect of treating the malignancy.
Original analysis of the supplied journal article, identified as PMC9312706.